Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IxCell hUC-MSC-S in Convalescent Ischemic Stroke
NCT05697718Phase 1Completed
- Sponsor
- iXCells Biotechnologies
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of IxCell in ischemic stroke (3 arms), sponsored by iXCells Biotechnologies. Primary endpoints: Safety and tolerability at 24 weeks, Blood routine laboratory test at 24 weeks and 6 more. Started Apr 2023; status: completed.
02
Drugs
IxCell
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05697718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697718.